- Home
- FEBO vs HSCS Comparison
FEBO vs HSCS Comparison
Compare FEBO & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEBO
- HSCS
- Stock Information
- Founded
- FEBO 1993
- HSCS 2007
- Country
- FEBO Hong Kong
- HSCS United States
- Employees
- FEBO N/A
- HSCS N/A
- Industry
- FEBO
- HSCS Medical Specialities
- Sector
- FEBO
- HSCS Health Care
- Exchange
- FEBO Nasdaq
- HSCS Nasdaq
- Market Cap
- FEBO 8.3M
- HSCS 9.9M
- IPO Year
- FEBO 2023
- HSCS 2022
- Fundamental
- Price
- FEBO $0.73
- HSCS $3.64
- Analyst Decision
- FEBO
- HSCS Strong Buy
- Analyst Count
- FEBO 0
- HSCS 2
- Target Price
- FEBO N/A
- HSCS $10.50
- AVG Volume (30 Days)
- FEBO 54.0K
- HSCS 93.8K
- Earning Date
- FEBO 10-24-2025
- HSCS 09-11-2025
- Dividend Yield
- FEBO N/A
- HSCS N/A
- EPS Growth
- FEBO N/A
- HSCS N/A
- EPS
- FEBO N/A
- HSCS N/A
- Revenue
- FEBO $17,110,653.00
- HSCS $6,250.00
- Revenue This Year
- FEBO N/A
- HSCS $13,968.97
- Revenue Next Year
- FEBO N/A
- HSCS $166.67
- P/E Ratio
- FEBO N/A
- HSCS N/A
- Revenue Growth
- FEBO 11.58
- HSCS N/A
- 52 Week Low
- FEBO $0.61
- HSCS $2.52
- 52 Week High
- FEBO $5.20
- HSCS $6.47
- Technical
- Relative Strength Index (RSI)
- FEBO 48.60
- HSCS 53.69
- Support Level
- FEBO $0.70
- HSCS $3.29
- Resistance Level
- FEBO $0.81
- HSCS $3.80
- Average True Range (ATR)
- FEBO 0.08
- HSCS 0.18
- MACD
- FEBO 0.00
- HSCS 0.02
- Stochastic Oscillator
- FEBO 56.90
- HSCS 68.63
About FEBO Fenbo Holdings Limited
Fenbo Holdings Ltd is a company engaged in producing premium personal care electric appliances, principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.